BGM0504
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
BrightGene Bio-Medical Technology Co · Phase 1 · Completed · Enrollment 80
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Cohort 1 | n/r | n/r | n/r | n/r | n/r |
| Cohort 2 | n/r | n/r | n/r | n/r | n/r |
| Cohort 3 | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
| Cohort 4 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.